Hypothesis

Aging selectively reduces the maximal velocity (Vmax) of carnitine acetyltransferase (CAT) in type II skeletal muscle fibers, lowering the capacity to buffer mitochondrial acetyl‑CoA. This deficit raises the mitochondrial acetyl‑CoA/CoA ratio, inhibiting pyruvate dehydrogenase and shifting metabolism toward incomplete fatty acid oxidation, while simultaneously diminishing nuclear acetyl‑carnitine–dependent histone acetylation that sustains atrophy‑resisting gene programs. Consequently, L‑carnitine supplementation improves muscle function only in individuals whose baseline CAT Vmax falls below a critical threshold, explaining the heterogeneous responses seen in prefrail versus healthy elderly cohorts.

Mechanistic Rationale

1. CAT as a metabolic buffer – CAT converts mitochondrial acetyl‑CoA and carnitine into acetyl‑carnitine and CoA, preventing acetyl‑CoA accumulation that would otherwise inhibit key dehydrogenases (PDH, α‑KGDH) and promote reductive stress. In young muscle, high CAT Vmax maintains a low acetyl‑CoA/CoA ratio, supporting flexible fuel use.
2. Age‑related CAT decline – Proteomic data show decreased CAT protein abundance in aging type II fibers (inferred from reduced carnitine‑acetylcarnitine exchange rates in older adults) [3]. Post‑translational modifications (e.g., oxidative sulfonation) further diminish catalytic efficiency, lowering Vmax without affecting Km for acetyl‑CoA.
3. Metabolic inflexibility – Reduced buffering raises mitochondrial acetyl‑CoA, inhibiting PDH and forcing reliance on glycolysis, which accelerates fatigue and promotes lactate‑induced inflammation. Simultaneously, excess acetyl‑CoA diverts to ketogenesis, producing acetyl‑carnitine that accumulates in the cytosol.
4. Nuclear signaling deficit – Acetyl‑carnitine serves as a cytosolic acetyl donor for nuclear ACSS2‑dependent histone acetylation. Lower CAT activity reduces acetyl‑carnitine efflux, diminishing nuclear acetyl‑carnitine pools and leading to hypoacetylation of promoters for PGC‑1α and FOXO3, genes that protect against atrophy. This epigenetic shift contributes to the strength loss observed in prefrail elders.
5. Supplementation efficacy – Raising intracellular carnitine via supplementation increases substrate for the residual CAT activity, temporarily boosting acetyl‑carnitine production and restoring both mitochondrial buffering and nuclear signaling—but only when enough catalytic capacity remains (i.e., CAT Vmax above a minimal threshold). Individuals with severely depleted CAT Vmax cannot convert the added carnitine, rendering supplementation ineffective.

Testable Predictions

• Prediction 1: In biopsies from older adults, CAT Vmax (measured by radiolabeled acetyl‑CoA conversion) will be significantly lower in type II fibers of non‑responders to L‑carnitine versus responders, while Km remains unchanged.
• Prediction 2: Responders will exhibit a ≥15 % increase in muscle acetyl‑carnitine and a concomitant decrease in mitochondrial acetyl‑CoA/CoA ratio after 24 weeks of supplementation; non‑responders will show no change.
• Prediction 3: Nuclear histone H3K9 acetylation at the PGC‑1α promoter will rise only in responders, correlating with improved grip strength.
• Prediction 4: Pharmacological inhibition of CAT in young mouse muscle will mimic the aging phenotype (reduced acetyl‑carnitine, lowered PDH activity, increased atrophy markers) and abolish the beneficial effect of L‑carnitine feeding.

Experimental Design

1. Human cohort: Recruit 60 older adults (65‑80 y) stratified by prefrailty status. Obtain vastus lateralis biopsies before and after 24 weeks of 1500 mg/day L‑carnitine (or placebo). Measure CAT Vmax and Km using freshly isolated mitochondria and ^14C‑acetyl‑CoA; quantify acetyl‑carnitine, acetyl‑CoA/CoA ratio, and histone acetylation via Western blot and ChIP‑qPCR. Correlate changes with functional outcomes (grip strength, gait speed).
2. Mouse validation: Use CAT‑floxed mice crossed with HSA‑Cre to inducibly delete CAT in adult skeletal muscle. Treat half with L‑carnitine (1 % w/w in drinking water) for 8 weeks. Assess mitochondrial flux (Seahorse), acetyl‑carnitine levels, histone acetylation, and muscle mass/strength.
3. Statistical analysis: Apply mixed‑effects models to test interaction between baseline CAT Vmax (continuous) and treatment on functional improvement. A significant interaction (p < 0.05) would confirm the threshold hypothesis.

If CAT Vmax predicts supplementation benefit, the field can move from empiric L‑carnitine dosing to precision nutrition guided by enzymatic phenotyping, resolving the current clinical heterogeneity.